Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

This phase I/II trial tests the effect of pegcetacoplan in combination with oxaliplatin, irinotecan, leucovorin, and fluorouracil (mFOLFIRINOX) in treating patients with pancreatic ductal adenocarcinoma (PDAC) that has spread from where it first started (primary site) to other places in the body (metastatic). Pegcetacoplan works by targeting the immune complement process, a part of the immune system that defends against bacteria and may limit tumor progression and improve the immune system's response against tumor cells. Oxaliplatin is in a class of medications called platinum-containing antin

Trial Details

NCT ID

NCT07214298

Phase

PHASE1 / PHASE2

Sponsor

Roswell Park Cancer Institute

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Biopsy Procedure
Biospecimen Collection
Computed Tomography
Fluorouracil
Irinotecan
Leucovorin Calcium

Locations (sample)

Buffalo, New York, United States|42.88645,-78.87837

Key Eligibility Criteria

Histologically or cytologically confirmed metastatic PDAC
Age ≥ 18 years of age
Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
Absolute neutrophil count ≥ 1,500/uL

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →